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Abstract
Background: Deregulated expression of oncogenes such as MYC and PAX3-FKHR often occurs in
rhabdomyosarcomas. MYC can enhance cell proliferation and apoptosis under specific conditions,
whereas PAX3-FKHR has only been described as anti-apoptotic.
Results: In order to evaluate how MYC and PAX3-FKHR oncogenes influenced p53-mediated
apoptosis, rhabdomyosarcoma cells were developed to independently express MYC and PAX3-
FKHR cDNAs. Exogenous wild-type p53 expression in MYC transfected cells resulted in apoptosis,
whereas there was only a slight effect in those transfected with PAX3-FKHR. Both oncoproteins
induced BAX, but BAX induction alone without expression of wild-type p53 was insufficient to
induce apoptosis. Data generated from genetically modified MEFs suggested that expression of all
three proteins; MYC, BAX and p53, was required for maximal cell death to occur.
Conclusion: We conclude that cooperation between p53 and oncoproteins to induce apoptosis
is dependent upon the specific oncoprotein expressed and that oncogene-mediated induction of
BAX is necessary but insufficient to enhance p53-mediated apoptosis. These data demonstrate a
novel relationship between MYC and p53-dependent apoptosis, independent of the ability of MYC
to induce p53 that may be important in transformed cells other than rhabdomyosarcoma.
Background
Rhabdomyosarcoma is the most common pediatric soft-
tissue sarcoma. The two main subtypes, embryonal and
alveolar, are characterized by specific morphologic fea-
tures and chromosomal translocations. Alveolar rhab-
domyosarcomas contain t(2;13) or t(1;13) translocations
that generate fusion genes encoding either PAX3 or PAX7
and forkhead (FKHR or FOXO1a) transcription factors
[1,2]. The resulting fusion proteins are much stronger
transcriptional activators than either PAX3 or PAX7 alone
[3]; such increased activity is thought to contribute to the
aggressive nature of alveolar rhabdomyosarcoma tumors
[4]. PAX3-FKHR expression enhances the proliferation
rate and invasiveness of rhabdomyosarcoma tumors [5],
and enhances expression of the anti-apoptotic protein
BCL-XL [6]. However, tumors with PAX3-FKHR  often
express other deregulated oncogenes [7,8], and Pax3-
FKHR knock-in mice do not develop tumors [9] suggest-
ing that the oncogenic potential of this fusion protein is
weak.
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Deregulated expression of members of the MYC family of
genes is the most common oncogenic change, other than
generation of PAX fusion proteins, observed in this tumor
type [7,8,10-12]. MYC proteins are involved in the regula-
tion of the cell cycle, proliferation, and apoptosis [13-18].
MYC proteins dimerize with MAX [19] and act as
sequence-specific transcriptional activators [20]. By acti-
vating the p14ARF/p53 pathway, MYC proteins induce
apoptosis [21]. Specifically, c-MYC activates ARF, which
then binds MDM2; thereby releasing p53 which induces
apoptosis [22]. In this manner, cells in which the ARF
pathway is functional are protected from the potential
transforming effects of MYC protein. However, MYC can
induce apoptosis through mechanisms independent of
p53 and ARF; for example, MYC can directly induce
expression of BAX [23] and ornithine decarboxylase [24],
induce release of cytochrome c from the mitochondria
[25], and play a role in the FAS apoptotic pathway [26].
ARF has also been shown to regulate MYC-mediated
apoptosis independent of p53 [27] but to date no rela-
tionship between MYC and p53-dependent apoptosis has
been described independent of ARF induction.
The goal of the present study was to evaluate how p53-
mediated apoptosis is influenced by the expression of two
different oncogenes, c-MYC and PAX3-FKHR. We demon-
strate that apoptosis can be enhanced in cells that express
c-MYC together with wild-type p53 and BAX, but that no
similar cooperation exists between PAX3-FKHR and p53
or BAX. In addition, data demonstrate that although c-
MYC can induce apoptosis in a p53-independent manner,
all three proteins, c-MYC, p53 and BAX are required to
induce maximal cell death.
Results
The JR1 rhabdomyosarcoma cell line was chosen for these
studies because it was derived from an embryonal tumor;
therefore, this line did not contain either the t(1;13) or the
t(2;13) translocations that are characteristic of the alveo-
lar subtype. In addition, barely detectable endogenous c-
MYC mRNA was observed upon Northern blot analysis,
and very low MYC-responsive promoter activity was
measured (data not shown). Generation of JR1 clones that
expressed PAX3-FKHR have been previously described by
Shetty et al. [28]. Clones of JR1 cells that expressed c-MYC
following transfection and G418 selection were chosen on
the basis of mRNA expression (Figure 1). Representative
data using c-MYC clone 5 are described.
To determine the effect of wild-type p53 expression on
survival of JR1 cells that expressed either c-MYC or PAX3-
FKHR, the clones were transduced with increasing concen-
trations of either Ad-p53 or Ad-VC adenoviral vectors.
Data were compared to those obtained from JR1 cells that
had been transfected with the parental vector (vector con-
trol cells, VC), i.e. those that did not express a transfected
oncogene. Expression of exogenous p53 resulted in
enhanced cell death compared to when the same cells
were transduced with Ad-VC (Figure 2). The c-MYC-
expressing cells were as sensitive to Ad-VC transduction as
were the control cells (Figure 2A). However, when the c-
MYC-expressing cells expressed exogenous wild-type p53
a significant increase in cell death was observed (Figure
2A). These data demonstrated cooperation between p53
and c-MYC in the induction of cell death (Figure 2A). In
contrast, the PAX3-FKHR-expressing cells were only
slightly more sensitive to Ad-p53 compared to Ad-VC
(Figure 2B) demonstrating very little cooperation between
p53 and PAX3-FKHR in the induction of cell death.
To determine whether the observed cell death was due to
apoptosis, we carried out cell cycle analysis to evaluate the
proportion of cells with a sub-G1 DNA content (Figure
3A). An increased proportion of the c-MYC-expressing
cells treated with Ad-p53 were in the sub-G1 fraction of the
cell cycle; therefore, we concluded that these cells were
apoptotic. The reduced proportion of cells in the G1 phase
in these samples also indicated that the observed reduc-
tion in cell number (Figure 2A) was from cell death, and
not p53-mediated growth arrest in the G1 phase of the cell
cycle (Figure 3B). Wild-type p53 expression in both the
PAX3-FKHR-expressing cells and the control cells resulted
in an accumulation of cells in G1 (Figure 3B) but not in
the sub-G1 phase (Figure 3A) of the cell cycle. Therefore,
the slight reduction in cell number measured in the cyto-
toxicity assays upon exogenous p53 expression in both of
these cell populations appeared to be due to a reduced
growth rate.
As an alternate indicator of apoptosis, Western blot anal-
yses were carried out to evaluate poly (ADP) ribose
polymerase (PARP) cleavage in MYC-expressing rhab-
domyosarcoma cells. Upon caspase 3 activation, PARP is
cleaved into 85 and 25 kDa subunits; the larger of the sub-
units can be detected by an anti-PARP antibody. There-
Northern blot analysis of JR1 clones transfected with c-MYC  cDNA using the c-MYC cDNA as a probe Figure 1
Northern blot analysis of JR1 clones transfected with c-MYC 
cDNA using the c-MYC cDNA as a probe. C indicates mRNA 
isolated from a control clone that had been transfected with 
the parental vector.Molecular Cancer 2006, 5:53 http://www.molecular-cancer.com/content/5/1/53
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fore, we indirectly assessed the status of caspase activation
by Western analysis to determine whether PARP had been
cleaved. PARP cleavage correlated with the accumulation
of cells in the sub-G1 phase of the cell cycle and the cyto-
A. Representative sub-G1 cell-cycle analysis of control cells,  c-MYC and PAX3-FKHR-expressing cells Figure 3
A. Representative sub-G1 cell-cycle analysis of control cells, 
c-MYC and PAX3-FKHR-expressing cells. Before analysis, 
the cells were either untreated (open bars) or exposed to 
either Ad-VC (m.o.i. 10, shaded bars) or Ad-p53 (m.o.i. 10, 
solid bars) for 24 h. B. Relative change in the proportion of 
cells in the G1 phase of the cell cycle 24 h after exposure to 
either Ad-VC (m.o.i. 10, shaded bars) or Ad-p53 (m.o.i. 10, 
solid bars). The values for the untreated cells were set to 
100 (open bars). A representative experiment is shown.
A. Cytotoxicity assay of the control (squares) and c-MYC- expressing (triangles) JR1 clones after transduction with Ad- p53 (solid line) and Ad-VC Figure 2
A. Cytotoxicity assay of the control (squares) and c-MYC-
expressing (triangles) JR1 clones after transduction with Ad-
p53 (solid line) and Ad-VC. (dashed line) B. Cytotoxicity 
assay of the control (squares) and PAX3-FKHR-expressing 
(triangles) JR1 clones after transduction with Ad-p53 (solid 
line) and Ad-VC (dashed line).Molecular Cancer 2006, 5:53 http://www.molecular-cancer.com/content/5/1/53
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toxicity assay data (Figures 2, 3, 4) demonstrating that cell
death was by apoptosis. A slight amount of PARP cleavage
was also detected in PAX3-FKHR-expressing cells exposed
to Ad-p53 demonstrating that a proportion of these cells
were also dying by apoptosis (Figure 4A). These data dem-
onstrate that measurement of PARP cleavage is a more
sensitive indicator of apoptosis than the other assays.
To evaluate whether the PAX3-FKHR cells were more
resistant to apoptosis induced by exposure to a genotoxic
agent, the three cell lines; control, c-MYC and PAX3-FKHR
expressing cells were exposed to 10 μM doxorubicin for 24
hours prior to analysis of cell viability by a propidium
iodide exclusion assay. Figure 4B demonstrates that the
PAX3-FKHR cells were slightly more sensitive to the cyto-
toxic effects of doxorubicin compared to the MYC express-
ing cells.
To evaluate whether expression of the pro-apoptotic pro-
tein  BAX  was induced upon exogenous expression of
either MYC or p53, the same Western membrane used to
evaluate PARP cleavage was incubated with anti-BAX anti-
bodies. Elevated BAX expression was observed in all cells
that expressed exogenous wild-type p53 or the c-MYC or
PAX3-FKHR oncogenes, including samples in which PARP
cleavage was not detected (Figure 4). Therefore, induction
of BAX is insufficient to induce apoptosis in the onco-
gene-expressing cells. Significant apoptosis was only
observed in the c-MYC-expressing cells when co-expressed
with p53. The same Western membrane was also incu-
bated with antibodies against p53 and p21Waf1/Cip1. High-
level expression of mutant p53 was observed in all clones,
and expression of functional exogenous wild-type p53
was demonstrated by the induction of the p53 target
genes, p21 and BAX.
MYC-induced apoptosis in certain model systems can be
inhibited by BCL-2 [29,30], a protein of the same family
that forms heterodimers and inactivates the pro-apoptotic
activity of BAX. Therefore, we evaluated the role of BAX in
the MYC-induced apoptosis observed in rhabdomyosar-
coma cells by analyzing the survival of cells following
transduction with Ad-BCL2 in combination with Ad-p53
(Figure 5). Elevated exogenous BCL-2 expression was
observed after transduction with Ad-BCL2 at an m.o.i. of
5 and 10 (Figure 5A). However, BCL-2 expression was
unable to protect the c-MYC-expressing cells from the
apoptotic effects of p53 (Figure 5B). The minimal effect of
exogenous BCL-2 expression on MYC-induced apoptosis
suggests that BAX plays little or no role in the cooperation
between p53 and c-MYC to induce apoptosis of rhab-
domyosarcoma cells.
To specifically evaluate cooperation between c-MYC, p53
and BAX in the induction of apoptosis, the relative contri-
A. Western blot analysis of the control, c-MYC- and PAX3- FKHR-expressing cells following exposure to either Ad-VC  or Ad-p53 (m.o.i. 10) Figure 4
A. Western blot analysis of the control, c-MYC- and PAX3-
FKHR-expressing cells following exposure to either Ad-VC 
or Ad-p53 (m.o.i. 10). B. Propidium iodide exclusion assay 
following exposure of the cells to 10 uM doxorubicin for 24 
h. Data are presented relative to untreated cells.Molecular Cancer 2006, 5:53 http://www.molecular-cancer.com/content/5/1/53
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bution of each was evaluated in MEFs. Bax-/- and Bax+/+
fibroblasts were used so that the effects of BAX on the
induction of apoptosis could be measured. Exogenous
wild-type p53 was expressed in these cells by transducing
with Ad-p53 (m.o.i. 100), and c-MYC expression was
introduced using the retrovirus MSCV-IRES-MYC-ER-GFP,
as described in the Methods section. Expression of each of
these proteins could be detected by Western analysis (Fig-
ure 6). Expression of c-MYC was detectable only in those
cells transduced with the MYC retrovirus, and p53 expres-
sion was only visible in cells transduced with Ad-p53.
Expression of p21 was evaluated as a measure of p53
activity, and although it is detectable in the BAX+/+ cells
upon Ad-p53 transduction, it is also visible in the BAX-/-
cells upon MYC expression. This result was surprising
because MYC has previously been shown to suppress p21
expression [31-33], but it does not influence interpreta-
tion of the data generated in this experiment. Measure-
ment of cell death of the BAX-/- and BAX+/+ cells
following p53 and c-MYC expression revealed that even
though MYC could induce cell death in a p53 independ-
ent manner, MYC, p53 and BAX proteins all played a role
in the induction of cell death (Figure 7). Maximal cell
death was only observed in cells that expressed all three
proteins; c-MYC, p53 and BAX.
Discussion
Rhabdomyosarcoma cells expressing one of the two onco-
proteins (c-MYC or PAX3-FKHR) responded in a different
manner to exogenous wild-type p53 expression (Figures 2
and 3). PAX3-FKHR has been previously characterized as
a relatively weak oncoprotein [9], with an anti-apoptotic
phenotype [6]. However in this study no anti-apoptotic
effects of PAX3-FKHR expression were observed. Instead
PAX3-FKHR weakly enhanced p53-mediated apoptosis.
The oncogenic potential of c-MYC is well characterized
[16-18], and an apoptotic phenotype has been described
[14,34]. Data presented here demonstrate that c-MYC
expression alone does not enhance apoptosis of JR1 cells;
co-expression with wild-type p53 is required, and this
combination resulted in the death of approximately 90%
of cells (Figures 2 and 3). A cooperation of wild-type p53
with MYC proteins to induce apoptosis has previously
been shown to be ARF-dependent [21] and ARF-inde-
pendent [35]. ARF binds MDM2 and sequesters it to the
nucleolus; thus, MDM2 releases control of p53, and p53
is no longer targeted for degradation by the proteasomal
pathway. As a result, p53 protein levels increase [22]. MYC
induction of p53 by an ARF-independent mechanism can
be mediated through the induction of p53 phosphoryla-
tion [35]. However, in the experiments described here p53
and MYC are expressed exogenously and therefore coop-
erate to induce apoptosis in a manner that is independent
of ARF and the ability of MYC to induce p53 expression.
BAX, a proapoptotic member of the BCL-2 family, is a
transcriptional target of p53 [36] and MYC [23]. However,
Figure 4 shows that elevated BAX expression was observed
in the PAX3-FKHR-expressing cells as well as those
expressing MYC, demonstrating that BAX can also be
induced by PAX3-FKHR. In the control cells that did not
A. Western blot analysis of BCL-2 expression in the c-MYC- expressing JR1 cells after transduction with either Ad-BCL2  or Ad-VC Figure 5
A. Western blot analysis of BCL-2 expression in the c-MYC-
expressing JR1 cells after transduction with either Ad-BCL2 
or Ad-VC. B. Cytotoxicity assay of the c-MYC-expressing 
cells after transduction with different combinations of adeno-
viral vectors. Cells were pretreated for 24 h with either Ad-
VC (m.o.i. 5, circles) or Ad-BCL2 (m.o.i. 5, diamonds) and 
then exposed to increasing m.o.i.s of either Ad-VC (dashed 
line) or Ad-p53 (solid line).Molecular Cancer 2006, 5:53 http://www.molecular-cancer.com/content/5/1/53
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Western blot analysis of Bax+/+ (A) and BAX-/- (B) MEFs following expression of c-MYC with and without wild-type p53 Figure 6
Western blot analysis of Bax+/+ (A) and BAX-/- (B) MEFs following expression of c-MYC with and without wild-type p53. 
Unt; untreated cells; R-VC; retrovirus vector control, R-c-MYC; retrovirus c-MYC.Molecular Cancer 2006, 5:53 http://www.molecular-cancer.com/content/5/1/53
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express either MYC or PAX3-FKHR, elevated BAX expres-
sion was observed only after Ad-p53 transduction. In the
cell lines expressing each of the oncoproteins, Ad-p53
transduction only minimally enhanced BAX protein
expression above the level induced by the oncogenes.
MYC reportedly cooperates with BAX to induce apoptosis
[37], and loss of BAX in a transgenic mouse model
impairs MYC-induced apoptosis and circumvents the
selection for p53 mutations during MYC-mediated lym-
phomagenesis [38]. However, the results presented in Fig-
ures 2, 3, 4 demonstrate that in the JR1
rhabdomyosarcoma cells increased BAX expression
induced by either c-MYC or PAX3-FKHR was insufficient
to induce apoptosis. The observation that elevated BAX
protein together with expression of wild-type p53 did not
significantly induce the death of PAX3-FKHR-expressing
cells demonstrated that a MYC component is required for
the induction of apoptosis by p53 in these cells. We con-
fimed that these results were oncogene specific by demon-
strating that the cells expressing either c-MYC or PAX3-
FKHR responded in a similar manner when exposed to
genotoxic damage (Figure 4B).
Caspase 3 has been shown to be involved in MYC-induced
apoptosis [39]. Indeed, our finding that cleavage of the
caspase 3 substrate, PARP, was associated with apoptosis
of JR1 cells suggested that caspase 3 also played a role in
MYC and p53-mediated cell death observed here.
Although BCL-2 has been previously shown to inhibit
MYC-induced apoptosis [29,30], BCL-2 expression in the
MYC-expressing cells did not decrease the proportion of
cells that died upon expression of p53 (Figure 5). These
data demonstrate that BCL-2 expression only minimally
affected the apoptosis of JR1 cells and together with the
observation that PAX3-FKHR induced BAX in the same
cells with minimal effects on apoptosis suggests that BAX
involvement in the MYC and p53-induced cell death is
limited. The lower level of p21 induced by p53 in the
MYC-expressing cells (Figure 4) is consistent with the
published report that MYC downregulates transcription of
the p21 promoter [31-33]. MYC suppression of p21 activ-
ity has been suggested as a mechanism by which p53 func-
tion can be switched from cytostatic to apoptotic [40,41].
This hypothesis is consistent with the results presented in
Figure 3, which demonstrate that the proportion of the
cell population undergoing apoptosis increased when the
G1 checkpoint was attenuated. However, p21 expression
was elevated in Bax-/- MEFs in response to c-MYC expres-
sion (Figure 6). This result does not support previously
published data and suggests differences in the response of
the rhabdomyosarcoma cells compared to MEFs with
respect to MYC expression.
Despite inherent differences in the cell types we evaluated
the relative contributions of MYC, p53 and BAX to the
induction of apoptosis in MEFs. Only by the use of genet-
ically modified cells, such as Bax-null MEFs, can the effects
of each of the three proteins be analyzed independently
(Figure 6). In the MEFs, MYC induced cell death inde-
pendent of wild-type p53. However, maximal cell killing
was observed only when all three proteins were expressed
together.
The process of immortalization often deregulates cellular
apoptotic pathways, for example MYC expression had no
effect on survival of JR1 rhabdomyosarcoma cells yet its
expression in Bax +/+ MEFs induced cell death. Neverthe-
less, the cooperation between p53 and MYC to induce
apoptosis was observed in both cell types demonstrating
that this apoptotic pathway remained intact in rhabdomy-
osarcoma cells.
Conclusion
From the data presented here we conclude that the ability
of wild-type p53 to induce apoptosis in any given cell type
is dependent upon the oncoprotein expressed and that
even though different oncoproteins may induce BAX, for
example PAX3-FKHR and MYC as shown here, elevated
BAX expression is insufficient to induce apoptosis.
Propidium iodide exclusion cell death assay data for BAX-/-  and BAX+/+ MEFs Figure 7
Propidium iodide exclusion cell death assay data for BAX-/- 
and BAX+/+ MEFs. Open bars represent cells that have not 
been exposed to any retroviral vector; shaded bars repre-
sent retrovirus vector control treated cells and solid bars 
represent c-MYC retrovirus treated cells. VC represents Ad-
VC treated cells and p53 represents Ad-p53 treated cells.Molecular Cancer 2006, 5:53 http://www.molecular-cancer.com/content/5/1/53
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Methods
Cell lines and transfections
JR1 embryonal rhabdomyosarcoma cells, which contain a
p53 Arg248Trp mutation [42], were established at the
Institute of Child Health, London, UK [43]. These cells
were grown in RPMI-1640 cell culture media supple-
mented with 10% fetal bovine serum (FBS) in a humidi-
fied environment at 37°C and 5% CO2, 95% air. The BAX-
/- and BAX+/+ mouse embryo fibroblasts (MEFs) were
obtained from John Cleveland (St. Jude Children's
Research Hospital, Memphis TN) and grown in DMEM
media supplemented with 10% FBS, 2% glutamine, 1%
non-essential amino acids and 1% β-mercaptoethanol
under the same conditions. These cells were grown to at
least passage 20 before use in the experiments described in
this paper in order to inactivate endogenous p53 activity.
The c-MYC cDNA was subcloned into the pIRESneo mam-
malian expression vector (Clontech, Palo Alto, CA), and
the resulting construct was transfected into JR1 cells using
the Profectin Mammalian Transfection System (Promega,
Madison WI). Individual clones resistant to 200 μg/ml
G418 were expanded, and their c-MYC mRNA expression
was evaluated by Northern blot analysis (Figure 1). Con-
trol cells that contained the parental vector were devel-
oped by transfection with the pIRESneo plasmid that did
not contain the c-MYC cDNA. Transcriptional activity of c-
MYC in the transfected clones was analyzed using a MYC-
responsive promoter reporter plasmid [44] and a dual
luciferase assay (Promega). We have previously described
the generation and characterization of JR1 cells expressing
the PAX3-FKHR cDNA [28]. RT-PCR showed that these
cells express PAX3-FKHR, and luciferase assays of cells that
had been transfected with a PAX-responsive luciferase
reporter plasmid demonstrated that PAX transcriptional
activity in the transfected clones was increased [28].
Viral vectors and cell transduction
Ad-p53 (Av1p53) was provided by Genetic Therapy Inc.
(a Novartis Company, Gaithersburg MD) [45]. Ad-VC and
Ad-Bcl2 were provided by Dr. Janet Houghton (St. Jude).
Cells were transduced with adenoviral vectors at the mul-
tiplicity of infection (m.o.i.) as described in the Results.
Retroviral plasmids; MSCV-IRES-MYC-ER-GFP and
MSCV-IRES-GFP, were obtained from John Cleveland (St.
Jude) and have previously been described [21]. These
plasmids were independently transiently transfected with
an ecotropic helper retroviral plasmid into 293T packag-
ing cells in order to generate retroviral particles. Retroviral
supernatant was harvested from the 293T cells at 24 and
48 h following transfection. This supernatant was filtered
and added to MEFs (at a dilution of 1:2) together with
hexadimethrinebromide (Polybrene, Sigma) at a final
concentration of 1 μg/ml. After 24 h 4-hydroxytamoxifen
(Sigma) was added to a final concentration of 1 μM to
induce MYC expression. Cells were harvested after a fur-
ther 24 h for Western and PI exclusion analyses.
Cytotoxicity assay and cell cycle analysis
Cells were plated in triplicate at a density of 1 × 105 per
well in 6-well plates. After a 24-h period of attachment,
cells were exposed to adenoviral vectors whose m.o.i.
ranged from 0.2 to 20. The total number of cells in each
well was counted after the untreated cells had doubled 3
times. Data are presented as a percentage of untreated
cells.
Cell cycle analysis was carried out on cells transduced with
virus (m.o.i. = 10) for 24 h. Cells were suspended at a con-
centration of 1 × 106/ml in a solution of propidium
iodide, and their DNA content was analyzed as previously
described [46]. Propidium iodide cell exclusion assays
were also carried out as a measure of cell death. Pelleted
cells were resuspended in the propidium iodide solution
used for DNA content analysis that did not contain any
Triton X-100, and analyzed by flow cytometry.
Northern and Western blot analyses
Northern blot analysis was conducted as described by
Sambrook et al. [47]. Cells for Western blot analysis were
transduced for 24 h with the adenoviral vectors at an
m.o.i. of 10. Cell extracts were prepared, and Western blot
analyses were performed as previously described [46]. The
p53 antibody (DO1-HRP) and the antibodies against
BAX, BCL-2, c-MYC and p21 were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA). The poly (ADP
ribose) polymerase (PARP) antibody was purchased from
PharMingen (San Diego, CA), and the β-tubulin antibody
was obtained from ICN Biomedicals, Inc (Aurora, OH).
Abbreviations
MEF, mouse embryo fibroblast; m.o.i., multiplicity of
infection; PARP, poly (ADP ribose) polymerase; VC, vec-
tor control.
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